Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of subcutaneous daxdilimab in inadequately controlled dermatomyositis or anti-synthetase inflammatory myositis
2022-502810-10-00Phase 2Completed
- Sponsor
- Horizon Therapeutics
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in dermatomyositis (DM) and antisynthetase syndrome (ASSD) comparing Daxdilimab with Placebo (2 arms). Primary endpoint: Total improvement score at Week 24. Started Jul 2023; status: completed.
02
Drugs
daxdilimab
03
Conditions
dermatomyositis (DM)antisynthetase syndrome (ASSD)
Beyond the preview
Go deeper on 2022-502810-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502810-10-00.